METTL3 and hepatoblastoma: Kwok et al. (2017) pointed out that, as a risky predictive prognosis biomolecule of acute myeloid leukemia, the downregulation of the ALKBH5 expression level is significantly correlated with TP53 mutation. METTL3, which is dramatically overexpressed in hepatoblastoma, modulates b-catenin to facilitate cancer cell proliferation (Liu et al., 2019).